Similar articles

• Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.

  Hanna GJ, Johnson VA, Kuritzkes DR, Richman DD, Brown AJ, Savara AV, Hazelwood JD, D'Aquila RT. Hanna GJ, et al. J Infect Dis. 2000 Mar;181(3):904-11. doi: 10.1086/315329. J Infect Dis. 2000. PMID: 10720511 Clinical Trial.
• Antiretroviral treatment for children with human immunodeficiency virus infection.

  Connor E. Connor E. Pediatrics. 1991 Aug;88(2):389-92. Pediatrics. 1991. PMID: 1907364 No abstract available.
• Continued zidovudine or didanosine for human immunodeficiency virus infection.

  Saitz R, Friedmann PD, Roberts MS. Saitz R, et al. N Engl J Med. 1992 Nov 26;327(22):1598; author reply 1599. doi: 10.1056/NEJM199211263272214. N Engl J Med. 1992. PMID: 1435891 Clinical Trial. No abstract available.
• The role of didanosine in the management of HIV-1 infection.

  Gazzard BG, Moyle GJ. Gazzard BG, et al. Antivir Ther. 1997 Jul;2(3):135-47. Antivir Ther. 1997. PMID: 11322269 Review.
• Update on reverse transcriptase inhibitors in HIV disease.

  Carr A, Loewenthal M, Cooper DA. Carr A, et al. Isr J Med Sci. 1993 Oct;29(10 Suppl):26-30. Isr J Med Sci. 1993. PMID: 7503966 Review. No abstract available.